Business, energy, technology, markets and global industry news from Business News Today

Edgewise Therapeutics

PharmaDeviceNews Edgewise Therapeutics
Pharma & Biotech

Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus

Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.

Read More
Representative image of a neuromuscular clinic consultation, reflecting Servier’s acquisition of Edgewise Therapeutics’ sevasemten programme and the growing race to develop oral therapies for Becker and Duchenne muscular dystrophy.
Pharma & Biotech

Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?

Servier is buying sevasemten before pivotal muscular dystrophy data. The deal gives Edgewise cash and investors a sharper cardiology story.

Read More